Your browser is no longer supported. Please, upgrade your browser.
Settings
PDSB [NASD]
PDS Biotechnology Corporation
Index- P/E- EPS (ttm)-0.71 Insider Own26.27% Shs Outstand22.26M Perf Week36.81%
Market Cap296.42M Forward P/E- EPS next Y-0.79 Insider Trans0.00% Shs Float16.43M Perf Month187.05%
Income-13.90M PEG- EPS next Q-0.17 Inst Own14.10% Short Float6.17% Perf Quarter135.53%
Sales- P/S- EPS this Y38.30% Inst Trans0.09% Short Ratio0.66 Perf Half Y489.91%
Book/sh1.09 P/B11.80 EPS next Y-16.20% ROA-49.20% Target Price10.52 Perf Year916.60%
Cash/sh1.08 P/C11.86 EPS next 5Y- ROE-55.90% 52W Range1.21 - 13.48 Perf YTD500.93%
Dividend- P/FCF- EPS past 5Y59.40% ROI- 52W High-4.60% Beta2.59
Dividend %- Quick Ratio9.30 Sales past 5Y- Gross Margin- 52W Low962.81% ATR1.49
Employees15 Current Ratio9.30 Sales Q/Q- Oper. Margin- RSI (14)65.94 Volatility12.96% 17.23%
OptionableYes Debt/Eq0.00 EPS Q/Q64.60% Profit Margin- Rel Volume1.13 Prev Close12.06
ShortableYes LT Debt/Eq0.00 EarningsMay 13 BMO Payout- Avg Volume1.53M Price12.86
Recom1.80 SMA2034.45% SMA5084.54% SMA200224.01% Volume2,076,851 Change6.63%
Nov-10-20Upgrade H.C. Wainwright Neutral → Buy $6
May-27-20Initiated Alliance Global Partners Buy $4
Mar-09-20Initiated Noble Capital Markets Outperform $5.45
Oct-24-19Initiated Chardan Capital Markets Buy $10
Jun-14-21 04:02PM  
08:00AM  
Jun-08-21 07:54AM  
07:44AM  
06:00AM  
Jun-07-21 08:00AM  
Jun-03-21 08:53AM  
Jun-01-21 08:27AM  
May-27-21 07:30AM  
May-24-21 03:47PM  
08:30AM  
08:07AM  
May-20-21 06:55PM  
08:00AM  
May-18-21 08:00AM  
May-17-21 08:00AM  
May-13-21 07:00AM  
05:45AM  
May-12-21 08:00AM  
Apr-29-21 08:30AM  
Apr-26-21 04:15PM  
Apr-19-21 09:22AM  
Mar-18-21 07:00AM  
06:15AM  
Mar-17-21 08:30AM  
Mar-11-21 08:30AM  
Mar-08-21 04:30PM  
Mar-03-21 04:30PM  
Feb-22-21 08:30AM  
Feb-03-21 12:42PM  
09:00AM  
Jan-14-21 08:30AM  
Jan-06-21 08:30AM  
Jan-05-21 08:45AM  
Dec-21-20 08:30AM  
Dec-09-20 08:30AM  
Nov-27-20 02:38PM  
Nov-16-20 08:30AM  
Nov-13-20 03:00PM  
Nov-12-20 06:15AM  
Nov-11-20 04:05PM  
Nov-10-20 04:05PM  
Nov-09-20 04:05PM  
Nov-05-20 04:05PM  
Oct-29-20 04:30PM  
Oct-26-20 08:30AM  
Oct-01-20 08:30AM  
Sep-28-20 08:30AM  
Sep-08-20 04:05PM  
Aug-31-20 08:30AM  
Aug-13-20 04:05PM  
06:00AM  
Aug-11-20 09:05AM  
Aug-10-20 04:05PM  
Aug-06-20 05:19PM  
Jul-30-20 04:05PM  
Jul-27-20 08:30AM  
Jul-14-20 08:30AM  
Jun-22-20 08:30AM  
Jun-17-20 08:30AM  
Jun-15-20 08:30AM  
Jun-14-20 11:43AM  
Jun-05-20 07:34AM  
Jun-04-20 04:05PM  
Jun-03-20 09:00AM  
Jun-02-20 08:30AM  
May-13-20 05:05PM  
06:00AM  
May-04-20 08:30AM  
Apr-30-20 07:19AM  
Apr-29-20 04:05PM  
Apr-16-20 08:30AM  
Apr-09-20 08:30AM  
Apr-02-20 12:00PM  
Mar-27-20 04:15PM  
Mar-23-20 04:45PM  
Mar-05-20 08:30AM  
Feb-27-20 08:30AM  
Feb-24-20 08:30AM  
Feb-17-20 08:30AM  
Feb-14-20 04:05PM  
Feb-12-20 09:18AM  
Feb-11-20 06:45PM  
Feb-05-20 04:05PM  
Dec-11-19 04:15PM  
04:05PM  
Dec-03-19 08:40AM  
Nov-25-19 08:30AM  
Nov-13-19 11:07AM  
Nov-07-19 06:00AM  
Nov-06-19 04:05PM  
Oct-22-19 08:30AM  
Oct-03-19 11:45AM  
08:30AM  
Oct-01-19 08:30AM  
Sep-19-19 08:00AM  
Sep-03-19 08:30AM  
Aug-01-19 06:00AM  
Jul-03-19 08:30AM  
Jun-19-19 08:30AM  
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.